Please use this identifier to cite or link to this item:
Title: Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list
Authors: Martina Penazzato
Claire L. Townsend
Natella Rakhmanina
Yao Cheng
Moherndran Archary
Tim R. Cressey
Maria H. Kim
Victor Musiime
Anna Turkova
Theodore D. Ruel
Helena Rabie
Nandita Sugandhi
Pablo Rojo
Meg Doherty
Elaine J. Abrams
Elaine Abrams
Jintanat Ananworanich
Isabelle Andrieux-Meyer
Yodit Belew
Brookie Best
Rosa Bologna
Jessica Burry
Deborah Carpenter
Polly Clayden
Angela Colbers
Magda Conway
Timothy R. Cressey
Mutsa Dangarembizi
Shaffiq Essajee
Maribel Gonzalez Tome
Andrew Hill
Saye Khoo
Maria Kim
Linda Lewis
Janice Lee
Shahin Lockman
Imelda Mahaka
Mark H. Mirochnick
Lynne Mofenson
Mireille Muhimpundu
Angela Mushavi
Elizabeth Obimbo
Fernando Pascual
Carmen Perez Casas
Anton Pozniak
Theodore Ruel
Jonathan Schapiro
George Siberry
Teresa Beatriz Simione
Cheick Tidiane Tall
Francois Venter
Marissa Vicari
Jenny Walsh
Jacque Wambui
Melynda Watkins
Keywords: Immunology and Microbiology
Issue Date: 1-Sep-2019
Abstract: © 2019 Elsevier Ltd Despite considerable progress in paediatric HIV treatment and timely revision of global policies recommending the use of more effective and tolerable antiretroviral regimens, optimal antiretroviral formulations for infants, children, and adolescents remain limited. The Paediatric Antiretroviral Drug Optimization group reviews medium-term and long-term priorities for antiretroviral drug development to guide industry and other stakeholders on formulations most needed for low-income and middle-income countries. The group convened in December, 2018, to assess progress since the previous meeting and update the list of priority formulations. Issues relating to drug optimisation for neonatal prophylaxis and paediatric treatment, and those relating to the investigation of novel antiretrovirals in adolescents and pregnant and lactating women were also discussed. Continued focus on identifying, prioritising, and providing access to optimal antiretroviral formulations suitable for infants, children, and adolescents is key to ensuring that global HIV treatment targets can be met.
ISSN: 23523018
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.